title: Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals.
abstract: Cisplatin (CIS) is one of the most effective anticancer drug used in the treatment of several solid tumors .Its use is limited by its nephrotoxicity. The present study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of CIS and the possible protective effect against CIS-induced nephrotoxicity in rats.
  
  
  
  The percent survival of female tumor bearing mice was used for determination the cytotoxic activity of CIS in the presence or the absence of RSVL. Uptake and cell cycle effect, serum creatinine (CREA), blood urea nitrogen (BUN), Reduced Glutathione (GSH) and histopatholgical examination of kidney tissues after CIS and/or RSVL therapy were also investigated.
  
  
  
  RSVL increased the intracellular level of CIS in EAC cells and there was a strong correlation between the high cellular level of CIS and its cytotoxicity. CIS at a dose level of 5 mg/kg increased the mean survival time of female tumor bearing mice to 25 days compared with 17 days for tumor-bearing control mice. Administration of RSVL at a dose level of 25 mg/kg simultaneously with CIS increased the mean survival time to 48 days with 60% survival of the tumor-bearing animals. Cell cycle analysis of tumor cells showed that CIS treatment decreases the proliferation index of tumor cells while in presence of RSVL there was more significant inhibitions. Also, CIS treatment caused increase in level of creatinine and blood urea with significant decrease in the GSH level. While, in the presence of RSVL, level of creatinine and blood urea restored to control level.
  
  
  
  This study suggests that RSVL could increase the cytotoxic activity of CIS and protect against its nephrotoxicity.
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia ; Pharmacology unit, National Cancer Institute, Cairo University, Cairo, 11796 Egypt.
authors.forename: Abdel-Moneim M
authors.initials: AM
authors.lastname: Osman
authors.forename: Suad A
authors.lastname: Telity
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Saud A
authors.initials: SA
authors.lastname: Telity
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Zoheir A
authors.initials: ZA
authors.lastname: Damanhouri
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Sameer E
authors.initials: SE
authors.lastname: Al-Harthy
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Huda M
authors.initials: HM
authors.lastname: Al-Kreathy
authors.affiliation: Anatomy Department, Faculty of Medicine, King Abdul Aziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Wafaa S
authors.initials: WS
authors.lastname: Ramadan
authors.affiliation: Department of biochemistry, Faculty of science, king abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia ; Molecular Biology and Genetic engineering and Biotechnology Department, Minoufia Universitym Minoufia, Minoufia, Egypt.
authors.forename: Mohamed F
authors.initials: MF
authors.lastname: Elshal
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Lateef M
authors.initials: LM
authors.lastname: Khan
authors.affiliation: Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
authors.forename: Fatemah
authors.initials: F
authors.lastname: Kamel
keywords: Cisplatin; Nephroprotection; Resveratrol